Monographie - Hydrochlorothiazide - Stabilis 4.0

Dernière mise à jour :
19/11/2024

Diurétique

Hydrochlorothiazide

Solution buvable

Stabilité des préparations

Stabilité en mélange

Facteur influençant la stabilité

Compatibilités

Bibliographie

pdf

Structure chimique

Solution buvable

Bibliographie

Solution buvable

Bibliographie : Hydrochlorothiazide

	Type	Source
2435	Revue	Allen LV, Jr, Erickson MA, Stability of labetalol hydrochloride, metoprolol tartrate, verapamil hydrochloride, and spironolactone with hydrochlorothiazide in extemporaneously compounded oral liquids Am J Health-Syst Pharm 1996 ; 53: 2304-2309.
3361	Revue	Santovena A, Hernandez-Paiz Z, Farina J.B. Design of a pediatric oral formulation with a low proportion of hydrochlorothiazide. Int J Pharm 2012 ; 423: 360-364.
3399	Poster	Li Y.Y, Postma D.J, Wagenaar H.W.G. Development of a hydrochlorothiazide 0.5 mg/mL oral solution for children. EAHP Congress Paris 2013
3910	Revue	Polonini H.C, Silva S .L, de Almeida T.R, Brand?o M.A, Ferreira A.O. Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions. EJHP 2016 ; 23: 352-358.
4177	Revue	Polonini H, Loures da Silva S, Fernandes Brandao M.A, Bauters T, De Moerloose B, De Oliveira Ferreira A. Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF PH4. Int J Pharm Compound 2018 ;22,6:516-526
4198	Revue	Uriel M, Gomez-Rincon C, Marro D. Stability of regularly prescribed oral liquids formulated with SyrSpend® SF. Pharmazie 2018 73;196-201
4256	Revue	Binson G, Beuzit K, Migeot V, Marco L, Troussier B, Venisse N, Dupuis A. Preparation and Physicochemical Stability of Liquid Oral Dosage Forms Free of Potentially Harmful Excipient Designed for Pediatric Patients. Pharmaceutics 2019 ;11,190:

Mentions Légales